April 20, 2017
Cash position and update on clinical developments for Q1 2017
Media
April 20, 2017
GenSight Biologics to Present GS010 at the 2017 Annual Meeting of the American Association of Neurology
April 20, 2017
Targovax initiates first clinical trial with TG02, the second product from its RAS-peptide immunotherapy platform
April 19, 2017
Targovax ASA: Invitation to first quarter 2017 results presentation Tuesday 25 April
April 19, 2017
GenSight Biologics to Attend Upcoming Investor Conferences
April 18, 2017
Cerenis Therapeutics announces the initiation of the Phase 1 clinical study with CER-209 in NAFLD and NASH
April 11, 2017
BONESUPPORT™ appoints Michael Diefenbeck as Chief Medical Officer
April 06, 2017
Report from Orexo AB´s annual general meeting, April 6 2017
April 06, 2017
Targovax to present clinical data on its phase I/II clinical trial evaluating TG01 in resected pancreatic cancer at the ASCO Annual Meeting
April 05, 2017
Final Phase 2 results for WTX101 accepted as a late-breaker presentation at EASL Annual Meeting